Pfizer Inc. $PFE Position Increased by Investment Partners LTD.

Investment Partners LTD. grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 105.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 33,323 shares of the biopharmaceutical company’s stock after buying an additional 17,140 shares during the quarter. Investment Partners LTD.’s holdings in Pfizer were worth $950,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Bank of America Corp DE acquired a new stake in shares of Pfizer in the second quarter worth about $1,049,602,000. BlackRock Inc. grew its holdings in shares of Pfizer by 6.3% in the 2nd quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock valued at $12,754,464,000 after acquiring an additional 31,412,883 shares in the last quarter. Nykredit A S bought a new stake in Pfizer in the 2nd quarter valued at $205,774,000. Assenagon Asset Management S.A. lifted its holdings in shares of Pfizer by 96.0% in the second quarter. Assenagon Asset Management S.A. now owns 11,902,374 shares of the biopharmaceutical company’s stock worth $286,609,000 after acquiring an additional 5,829,204 shares during the last quarter. Finally, State Street Corp raised its stake in Pfizer by 1.8% during the second quarter. State Street Corp now owns 307,090,897 shares of the biopharmaceutical company’s stock worth $7,394,749,000 after buying an additional 5,501,032 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer reported that its Phase 3 MagnetisMM-32 trial of ELREXFIO met its primary endpoint in patients with relapsed or refractory multiple myeloma. The result supports another potential growth driver for Pfizer’s oncology portfolio. The FDA also expanded the use of TALZENNA plus XTANDI for certain men with metastatic hormone-sensitive prostate cancer, increasing the commercial opportunity for the combination. Pfizer cancer trial and FDA approval article
• Positive Sentiment: New real-world data from China showed continued momentum for lorlatinib in lung cancer treatment, potentially reinforcing the drug’s adoption and durability outside clinical-trial settings. Lorlatinib China study article
• Positive Sentiment: Pfizer launched a Phase 1 trial for Alzheimer’s candidate PF-08161842, adding a new early-stage asset to its pipeline. Although the program is years from potential commercialization, it gives investors another source of long-term optionality. PF-08161842 Alzheimer’s trial article
• Neutral Sentiment: Investors are focused on Pfizer’s third-quarter earnings report, scheduled for November 3. Attention will center on whether non-COVID products and pipeline progress can offset continuing declines in pandemic-related revenue. Pfizer Q3 earnings outlook article
• Negative Sentiment: Analysts remain cautious ahead of earnings, while commentary highlights that Pfizer’s nearly 6% dividend yield exceeded free cash flow in the prior year. That raises questions about long-term payout coverage, even though the dividend remains attractive to income-focused investors. Pfizer dividend safety article

Pfizer Stock Performance

Shares of PFE stock opened at $30.48 on Friday. Pfizer Inc. has a one year low of $23.62 and a one year high of $30.67. The company has a fifty day moving average price of $28.55 and a two-hundred day moving average price of $26.79. The stock has a market cap of $173.73 billion, a P/E ratio of 40.11, a P/E/G ratio of 2.07 and a beta of 0.32. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating the consensus estimate of $0.68 by $0.09. The firm had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities analysts predict that Pfizer Inc. will post 2.94 EPS for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 7th. Stockholders of record on Friday, November 6th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 5.6%. The ex-dividend date of this dividend is Friday, November 6th. Pfizer’s payout ratio is 226.32%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on PFE shares. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research report on Tuesday, October 13th. JPMorgan Chase & Co. raised their target price on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a report on Friday, October 9th. Bank of America decreased their target price on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. Scotiabank upped their target price on shares of Pfizer from $30.00 to $33.00 and gave the company an “outperform” rating in a report on Tuesday, October 6th. Finally, Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Saturday, October 10th. Five analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $28.65.

Pfizer Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.